BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme
BMS will pay Agenus $200m upfront and up to $1.36bn in development, regulatory and commercial milestones
Read More
Tag: Agenus
Gilead & Agenus form $1.8bn partnership
Gilead Sciences and Agenus have announced a partnership to focus on the development and commercialisation of up to five novel immuno-oncology therapies.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
